Our Connecticut-Based U.S. Innovation Hub

“At the Ridgefield Innovation Unit, and in partnership with our global team of scientists, we foster creativity and put the patient at the center of our work. As an independent company, we have the freedom to follow our long-term vision – not the stock market – which allows us to lead the science and identify transformative treatments within and beyond our current research and development focus. Our scientific breakthroughs are a testament to this mindset.” – Dr. Carine Boustany, Senior Vice President, Site Head Discovery Research U.S. & Head of Global Immunology & Respiratory

“It’s easy to forget that our campus is within driving distance of both New York City and Boston. Like the renown academic centers around us – several of which we partner with – Boehringer Ingelheim conducts cutting edge research and development activities with the potential to improve the lives of patients around the world. Our talented scientists and leaders, together with our external partners, are continually creating value through innovation.” – Dr. Xiaorong He, Site Head Development U.S. and Global Head of Development Sciences

“Our Translational Medicine and Clinical Pharmacology team is collaborative and patient driven. Our biomarker team partners with our Research colleagues to build new therapeutic concepts into the right patient populations utilizing biomarker and imaging approaches. Our Clinical Pharmacology team works to characterize small and large molecule drugs in healthy volunteers and patients in early and late phase trials. This is in partnership with our Pharmacometrics team, who is responsible for modelling the pharmacokinetics and pharmacodynamics of these small and large molecule drugs to determine the appropriate doses to move forward in later phase clinical trials.”  – Dr. Sudha Visvanathan, Vice President, Translational Medicine & Clinical Pharmacology (TMCP) Inflammation/TMCP U.S.